<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" dtd-version="1.3" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <front>
    <journal-meta>
      <journal-title-group>
        <journal-title>Journal of Nanoscience and Nanomaterials</journal-title>
      </journal-title-group>
      <issn pub-type="epub">3108-2084</issn>
      <abbrev-journal-title abbrev-type="publisher">JNNC</abbrev-journal-title>
      <publisher>
        <publisher-name>Confmeets Publishing, an imprint of Conve International Pvt Ltd</publisher-name>
        <publisher-loc>Visakhapatnam, Andhra Pradesh, India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <article-id pub-id-type="doi">10.67238/jnnc.2026.v2.09</article-id>
      <article-id pub-id-type="publisher-id">JNNC-26-2529</article-id>
      <title-group>
        <article-title>Nanoparticles in the Treatment of Virus- A Broad Study</article-title>
      </title-group>
      <pub-date pub-type="epub">
        <day>16</day>
        <month>10</month>
        <year>2026</year>
      </pub-date>
      <volume>2</volume>
      <issue>1</issue>
      <fpage>85</fpage>
      <lpage>91</lpage>
      <counts>
        <page-count count="7"/>
      </counts>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>06</month>
          <year>2026</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>08</month>
          <year>2026</year>
        </date>
        <date date-type="pub">
          <day>16</day>
          <month>10</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0/" license-type="open-access">
          <license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="https://www.confmeets.com/journals/jnnc/articles/JNNC-26-2529-5.pdf"/>
      <aff id="aff1">
        <institution-wrap>
          <institution>Department of Polymer Science &amp; Technology, University of Calcutta, Kolkata, India</institution>
        </institution-wrap>
      </aff>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Yeasmin</surname>
            <given-names>Sabina</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <abstract>
        <p>Viruses impact on healthcare and socioeconomic development. In a public health care system drug resistance are currently are available different therapies. Adverse side effects due to prolonged use is a serious public health concern. Novel treatment strategies developed. The interactions of nanostructures with microorganisms is fast revolutionizing the biomedical field by offering advantages in both diagonostic and therapeutic applications. Nanoparticles have unique properties that can help in drug delivery. The properties of nanoparticles that depend on others are particle size distribution, surface to volume ratio and surface charge depend on encapsulation. This properties can make nanoparticle drug delivery systems to explore therapeutic effects. This review present how to treat viral infections with nanosized materials.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Nanosized Materials</kwd>
        <kwd>Liposomes</kwd>
        <kwd>Micelles</kwd>
        <kwd>Viral Infection</kwd>
        <kwd>Gold Nanoparticles</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Infectious disease agents such as bacteria, viruses, fungi and parasites account for approximately 15 million deaths worldwide, with acute respiratory infection and human immunodeficiency virus (HIV) being the leading causes [1,2]. Viral infections can help in both health and socioeconomic development [3]. Drug resistance evolved as it is associated with HIV and influenza infection <xref ref-type="bibr" rid="ref4">4</xref>-<xref ref-type="bibr" rid="ref8">8</xref>. This phenomenon included morbidity and mortality added costs associated with the use of more expensive drugs and a greater burden to public health systems [2,9]. A novel method develop to treat viral infections.</p>
      <p>Nanoparticles are particles that belong to the nanometer range [10,11]. The interaction between nanoscience and biological systems is known as nanobiotechnology [12,13]. It is associated with nanomedicine and diagnose, treatment and prevention of diseases [14].</p>
      <p>We are going to introduce here dose limiting biocompatible drugs [15]. For its small size it can invade cell easily [11,16]. Large surface area to volume ratio, surface charge make it a strong weapon to treat viral infections [17,18,19]. Nanoparticles also have some anti-viral properties [20-24]. It also can act as dendrimers [25,26]. It can be able to formation of stable structure [27,28]. It can also modified the structure of polymers [29]. It can also increase stability and the drug retention times <xref ref-type="bibr" rid="ref30">30</xref>,<xref ref-type="bibr" rid="ref31">31</xref>. This nanoparticles can invade cell and act in the cellular components [30,31,32]. Nanoparticle act as a drug carrier in case of RNA system also. It will act as a carrier in the blood-brain barrier also. It leads to low level replication [33,34]. It also can invade the obstacle and act as a promising tool against membranes [35]. To invade all this problem RNA technology is necessary [36]. The inability of RNA to cross the cell membrane, due to large molecular weight and anionic charge rapid renal clearance, uptake by phagocytes, and toxicity due to stimulated immune response [37,38,39] all present limitations which prohibits their clinical utility. This review will provide an overview of the most recent and relevant literature that describes the application of nanotechnology for the treatment of common viral infections.</p>
      <sec>
        <title>Biocompatible Systems</title>
        <p>&#13;
  <bold>Organic nanoparticles</bold>&#13;
</p>
        <p>Organic nanoparticles are most common nanoparticle in drug delivery in humans [40-43]. The most common types of organic nanoparticles are presented below</p>
        <p>&#13;
  <bold>Polymeric nanoparticles</bold>&#13;
</p>
        <p>Polymeric nanoparticles are particles ranging in size from 10-1000 nm. The small size result in capillary penetrations at target sites [44-49]. Polymers approved by the WHO and FDA use in medicine and pharmaceuticals include PLA, PGA and PLGA [50]. PLG and PLGA based nanoparticles are used for biocompatibility and biodegradability purposes [51]. It can interact with serum proteins decrease the opsonization [52,53]. The pharmacokinetic profile and gold-standard of cloaking agent systems can also be represented here [54,55]. Polymeric nanoparticles can be classified as nanocapsules and nanospheres.</p>
        <fig id="fig1">
          <label>Figure 1</label>
          <caption>
            <p>Polymeric Nanoparticle Shaped in Spherical Structure</p>
          </caption>
          <graphic xlink:href="https://s3.amazonaws.com/confmeets/art_full_text_img/JNNC-26-2529_5_522_1791193551.png"/>
        </fig>
        <fig id="fig2">
          <label>Figure 2</label>
          <caption>
            <p>Structure of Nanocapsule</p>
          </caption>
          <graphic xlink:href="https://s3.amazonaws.com/confmeets/art_full_text_img/JNNC-26-2529_5_523_1791193565.png"/>
        </fig>
        <fig id="fig3">
          <label>Figure 3</label>
          <caption>
            <p>Structure of Nanosphere</p>
          </caption>
          <graphic xlink:href="https://s3.amazonaws.com/confmeets/art_full_text_img/JNNC-26-2529_5_523_1791193565.png"/>
        </fig>
        <p>&#13;
  <bold>Liposomes</bold>&#13;
</p>
        <p>Liposomes are spherical carriers ranging in size from 20-30 nm [63]. A phospholipid bilayer is there contain an aqueous core [64]. Hydrophilic and lipophilic drugs can also be incorporated into the phospholipid bilayer [65]. It can also be act as an immunological parts [66].</p>
        <p>&#13;
  <bold>Micelles</bold>&#13;
</p>
        <p>Micelles are ranging in size from 10 -100 nm [57]. Polymeric micelles are working as drug delivery agents which have significant therapeutic potential [67-69]. Drug encapsulation with polymeric micelles is one of the most attractive nanotechnologies used to improve both the water solubility and stability of limited drugs [70].</p>
        <p>&#13;
  <bold>Dendrimers</bold>&#13;
</p>
        <p>Dendrimers are symmetrical, macromolecular and hyper-branched structure having connectors and branching units that target environment is controlled by the terminal groups [71]. Central core, branches and functional groups can have the ability to display multivalent surface [72].</p>
      </sec>
      <sec>
        <title>Sold Liipid Nanoparticles</title>
        <p>Solid lipid nanoparticles are alternative drug delivery system to the conventional colloidal nanoparticles. It can also combine with other nanoparticles and uses in drug delivery systems. Large-scale production of polymeric nanoparticles is a major challenge, production is cost-effective [73]. Stability, safety, availability, decreased toxicity can improve drug-profiles in compared to synthetic polymer nanoparticles [74-76].</p>
      </sec>
      <sec>
        <title>Inorganic Nanoparticles</title>
        <p>Inorganic nanoparticles are smaller in size than organic nanoparticles [35]. The top-down approach uses chemical or physical methods to reduce the inorganic material to its nanosized form [77].</p>
        <fig id="fig4">
          <label>Figure 4</label>
          <caption>
            <p>Structure of Inorganic Nanoparticle</p>
          </caption>
          <graphic xlink:href="https://s3.amazonaws.com/confmeets/art_full_text_img/JNNC-26-2529_5_524_1791193581.png"/>
        </fig>
      </sec>
      <sec>
        <title>Gold Nanoparticles</title>
        <p>Gold nanoparticles (GNPs) are widely researched as nanocarriers due to their excellent conductivity flexibility of surface modification, biocompatibility, and simplistic preparation methods [78]. The unique physical and chemical properties include the gold core, nahotophysical properties and thiol linkages [79,80,81]. During GNPs preparation it can produce versatile ranges of nanoparticles [82-87].</p>
        <fig id="fig5">
          <label>Figure 5</label>
          <caption>
            <p>Spherical Structure of Gold Nanoparticles</p>
          </caption>
          <graphic xlink:href="https://s3.amazonaws.com/confmeets/art_full_text_img/JNNC-26-2529_5_526_1791193611.png"/>
        </fig>
        <fig id="fig6">
          <label>Figure 6</label>
          <caption>
            <p>Structure of Silver Nanoparticles</p>
          </caption>
          <graphic xlink:href="https://s3.amazonaws.com/confmeets/art_full_text_img/JNNC-26-2529_5_526_1791193611.png"/>
        </fig>
        <p>&#13;
  <bold>Other metallic nanoparticles</bold>&#13;
</p>
        <p>Various other metallic nanoparticles such as titanium,zinc,and copper, as well as metal oxide nanoparticles such as iron oxide, zinc oxide, and titanium dioxide have demonstrated specific antiviral activities. Others, like platinum nanoparticles, which are used for the detection of influenza virus, are yet to be evaluated [93-97].</p>
      </sec>
      <sec>
        <title>Virology</title>
        <p>All this nanoparticles are use for the treatment of different viruses [98-103].</p>
        <table-wrap id="tbl1">
          <table>
            <tbody>
              <tr>
                <td> &#13;
        &#13;
        &#13;
           &#13;
        &#13;
        &#13;
           </td>
                <td>Company</td>
                <td>Description</td>
                <td>Mechanism of action</td>
                <td>Indication</td>
                <td>Approval year/stage of development</td>
                <td>Reference</td>
              </tr>
              <tr>
                <td>Inflexal V®</td>
                <td>Crucell, Berna Biotech</td>
                <td>Virosomal (150 nm liposomes) vaccine</td>
                <td>Mimicking native antigen presentation: Liposomes mimic the native virus structure, thus allowing for cellular entry and membrane fusion  Retention of the natural presentation of antigens on liposomal surface provides for high immunogenicity.</td>
                <td>Influenza</td>
                <td>1997</td>
                <td>Herzog,&#13;
         Mischler, Metcalfe, Bachmann andJennings <xref ref-type="bibr" rid="ref104">104</xref>-<xref ref-type="bibr" rid="ref106">106</xref></td>
              </tr>
              <tr>
                <td>Epaxal®</td>
                <td>Crucell, Berna Biotech</td>
                <td>Inactivated virosomal (liposome) vaccine</td>
                <td>Unique mechanism of action which mimics the natural process</td>
                <td>HAV</td>
                <td>1999</td>
                <td>Bovier <xref ref-type="bibr" rid="ref107">107</xref></td>
              </tr>
              <tr>
                <td>PegIntron®</td>
                <td>Merck</td>
                <td>PEGylated interferon alfa-2b</td>
                <td>Improved stability of protein through PEGylation</td>
                <td>HCV</td>
                <td>2001</td>
                <td>Alconcel <xref ref-type="bibr" rid="ref108">108</xref></td>
              </tr>
              <tr>
                <td>Pegasys®</td>
                <td>Genentech</td>
                <td>PEGylated interferon alfa-2b</td>
                <td>Improved stability of protein through PEGylation</td>
                <td>HBV, HCV</td>
                <td>2002</td>
                <td>Alconcel <xref ref-type="bibr" rid="ref108">108</xref></td>
              </tr>
              <tr>
                <td>Influvac® Plus</td>
                <td>Solvay Pharma/Abbott</td>
                <td>Virosome vaccine</td>
                <td>Containing influenza surface proteins neuraminidase and hemagglutinin</td>
                <td>Influenza</td>
                <td>2005</td>
                <td>Waknine <xref ref-type="bibr" rid="ref109">109</xref></td>
              </tr>
              <tr>
                <td>Fluquit TM&#13;
           (STP 702)</td>
                <td>Sirnaomics Inc.</td>
                <td>Short interfering RNA  (SiRNA) therapeutic</td>
                <td>Gene silencing</td>
                <td>H5N1 and H1N1 influenza</td>
                <td>Preclinical evaluation</td>
                <td>Sirnaomics <xref ref-type="bibr" rid="ref110">110</xref></td>
              </tr>
              <tr>
                <td>Cervisil®  (STP 909)</td>
                <td>Sirnaomics Inc.</td>
                <td>Short interfering RNA  (SiRNA) therapeutic</td>
                <td>Gene silencing</td>
                <td>HPV</td>
                <td>Preclinical evaluation</td>
                <td>Sirnaomics <xref ref-type="bibr" rid="ref110">110</xref></td>
              </tr>
              <tr>
                <td>VivaGel®  (SPL 7013)</td>
                <td>Starpharma</td>
                <td>Dendrimer</td>
                <td>Lysine-based dendrimer with naphthalene disulfonic acid surface groups</td>
                <td>HIV, HSV</td>
                <td>Clinical trial  (number: NCT00740584) (approved for used against bacterial vaginosis)</td>
                <td>Starpharma <xref ref-type="bibr" rid="ref111">111</xref></td>
              </tr>
              <tr>
                <td>DermaVir</td>
                <td>Genetic Immunity</td>
                <td>Therapeutic vaccine</td>
                <td>Synthetic plasmid DNA immunogen expressing 15 antigens, inducing significant expansions of the HIV-specific precursor/memory T cell pool.</td>
                <td>HIV</td>
                <td>Clinical trial  (number  NCT00270205)</td>
                <td>Rodriguez <xref ref-type="bibr" rid="ref112">112</xref></td>
              </tr>
              <tr>
                <td>Doravirine  (MK-1439)</td>
                <td>Merck</td>
                <td>Solid drug nanoparticle formulation</td>
                <td>Non-nucleoside reverse transcriptase inhibitor</td>
                <td>HIV</td>
                <td>Clinical trial  (number: NCT02549040)</td>
                <td>Molina <xref ref-type="bibr" rid="ref113">113</xref></td>
              </tr>
              <tr>
                <td>ARB-001467 TKM-HBV</td>
                <td>Arbutus Biopharma</td>
                <td>Wet lipid nanoparticle</td>
                <td>Lipid particle containing three RNAi  therapeutics that target three sites on the HBV genome</td>
                <td>HBV</td>
                <td>Clinical trial  (number: NCT02631096)</td>
                <td>Seto <xref ref-type="bibr" rid="ref114">114</xref></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
    </sec>
    <sec>
      <title>CONCLUSION</title>
      <p>We can conclude that nanoparticles have antiviral effect also. For its small size it can invade cell easily. The system use for the synthesis of nanoparticles are extremely retain its property on the nanoparticles. Shape is generally spherical. It can invade cell and help in the treatment. We are providing here a lot of result that can reduce silver, gold particles and make them nanoparticles. Spherical nanoparticles have antiviral effect proven in this review. They can cure many diseases. Once it prepared stored in a dark place. So that it stay good for a long time.  If you want to cure viral diseases you can use plant extracts for the preparation of nanoparticles. Will you ever seen such a different type of nanoparticles synthesis and characterization medication and cure for the patient.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <mixed-citation>Panáček A, Kolář M, Večeřová R, Prucek R, Soukupová J, Kryštof V, et al. Antifungal activity of silver nanoparticles against Candida spp. Biomaterials. 2009;30(31):6333-6340</mixed-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <mixed-citation>Qasim M, Lim DJ, Park H, Na D. Nanotechnology for diagnosis and treatment of infectious diseases. J Nanosci Nanotechnol. 2014;14(10):7374-7387</mixed-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <mixed-citation>Mehendale R, Joshi M, Patravale VB. Nanomedicines for treatment of viral diseases. Crit Rev Ther Drug Carrier Syst. 2013;30(1):1-49</mixed-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <mixed-citation>Little SJ, Holte S, Routy JP, Mayer KH, Connors M, Walker BD, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394</mixed-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <mixed-citation>Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21(2):215-223</mixed-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <mixed-citation>Lockhat HA, Silva JR, Alves CN, Lameira J. Binding free energy calculations of nine FDA-approved protease inhibitors against HIV-1 subtype C I36T† containing 100 amino acids per monomer. Chem Biol Drug Des. 2016;87(4):487-498</mixed-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <mixed-citation>Maseko SB, Natarajan S, Sharma V, Bhattacharyya N, Govender T, Sayed Y, et al. Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies. Protein Expr Purif. 2016;122:90-96</mixed-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <mixed-citation>Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(Suppl 1):S3-S13</mixed-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <mixed-citation>Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(Suppl 2):S82-S89</mixed-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <mixed-citation>Nalwa HS, editor. Handbook of nanostructured materials and nanotechnology. Vol. 1. San Diego: Academic Press; 1999. p. 1-3</mixed-citation>
      </ref>
      <ref id="ref11">
        <label>11</label>
        <mixed-citation>Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses. 2012;4(4):488-520</mixed-citation>
      </ref>
      <ref id="ref12">
        <label>12</label>
        <mixed-citation>Scheller FW, Bier FF, Pfeiffer D. Biosensoren: Grundlagen und Anwendungen. Tech Mess. 1995;62(1):213-219</mixed-citation>
      </ref>
      <ref id="ref13">
        <label>13</label>
        <mixed-citation>Niemeyer CM, Mirkin CA, editors. Nanobiotechnology: concepts, applications and perspectives. Vol. 1. Weinheim: Wiley-VCH; 2004</mixed-citation>
      </ref>
      <ref id="ref14">
        <label>14</label>
        <mixed-citation>Medepalli KK. Advanced nanomaterials for biomedical applications [dissertation]. Cambridge: ProQuest; 2008</mixed-citation>
      </ref>
      <ref id="ref15">
        <label>15</label>
        <mixed-citation>Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond). 2013;8(3):449-467</mixed-citation>
      </ref>
      <ref id="ref16">
        <label>16</label>
        <mixed-citation>Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials. 2012;33(4):1180-1189</mixed-citation>
      </ref>
      <ref id="ref17">
        <label>17</label>
        <mixed-citation>McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol Biol. 2011;697:3-8</mixed-citation>
      </ref>
      <ref id="ref18">
        <label>18</label>
        <mixed-citation>Caron J, Reddy LH, Lepêtre-Mouelhi S, Wils P, Desmaële D, Couvreur P. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. Bioorg Med Chem Lett. 2010;20(9):2761-2764</mixed-citation>
      </ref>
      <ref id="ref19">
        <label>19</label>
        <mixed-citation>Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615-627</mixed-citation>
      </ref>
      <ref id="ref20">
        <label>20</label>
        <mixed-citation>Gagliardi M. Biomimetic and bioinspired nanoparticles for targeted drug delivery. Ther Deliv. 2017;8(5):289-299</mixed-citation>
      </ref>
      <ref id="ref21">
        <label>21</label>
        <mixed-citation>Sanvicens N, Marco MP. Multifunctional nanoparticles – properties and prospects for their use in human medicine. Trends Biotechnol. 2008;26(8):425-433</mixed-citation>
      </ref>
      <ref id="ref22">
        <label>22</label>
        <mixed-citation>Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc. 2008;130(22):6896-6897</mixed-citation>
      </ref>
      <ref id="ref23">
        <label>23</label>
        <mixed-citation>Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun (Camb). 2005;(40):5059-5061</mixed-citation>
      </ref>
      <ref id="ref24">
        <label>24</label>
        <mixed-citation>Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8:1</mixed-citation>
      </ref>
      <ref id="ref25">
        <label>25</label>
        <mixed-citation>Mallipeddi R, Rohan LS. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine. 2010;5:533-547</mixed-citation>
      </ref>
      <ref id="ref26">
        <label>26</label>
        <mixed-citation>Wang W, Guo Z, Chen Y, Liu T, Jiang L. Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/TAR RNA binding in HIV-1 transcription. Chem Biol Drug Des. 2006;68(6):314-318</mixed-citation>
      </ref>
      <ref id="ref27">
        <label>27</label>
        <mixed-citation>Chiappetta DA, Facorro G, de Celis ER, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine. 2011;7(5):624-637</mixed-citation>
      </ref>
      <ref id="ref28">
        <label>28</label>
        <mixed-citation>Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18(3):241-268</mixed-citation>
      </ref>
      <ref id="ref29">
        <label>29</label>
        <mixed-citation>Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515</mixed-citation>
      </ref>
      <ref id="ref30">
        <label>30</label>
        <mixed-citation>Santos-Martinez MJ, Rahme K, Corbalan JJ, Faulkner C, Holmes JD, Tajber L, et al. Pegylation increases platelet biocompatibility of gold nanoparticles. J Biomed Nanotechnol. 2014;10(6):1004-1015</mixed-citation>
      </ref>
      <ref id="ref31">
        <label>31</label>
        <mixed-citation>Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4):987-992</mixed-citation>
      </ref>
      <ref id="ref32">
        <label>32</label>
        <mixed-citation>Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond). 2009;4(1):105-118</mixed-citation>
      </ref>
      <ref id="ref33">
        <label>33</label>
        <mixed-citation>De Oliveira MP, Garcion E, Venisse N, Benoit JP, Couet W, Olivier JC. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 mice. Pharm Res. 2005;22(11):1898-1905</mixed-citation>
      </ref>
      <ref id="ref34">
        <label>34</label>
        <mixed-citation>Hellmuth J, Valcour V, Spudich S. CNS reservoirs for HIV: implications for eradication. J Virus Erad. 2015;1(2):67-71</mixed-citation>
      </ref>
      <ref id="ref35">
        <label>35</label>
        <mixed-citation>Mahajan SD, Aalinkeel R, Law WC, Reynolds JL, Nair BB, Sykes DE, et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine. 2012;7:5301-5314</mixed-citation>
      </ref>
      <ref id="ref36">
        <label>36</label>
        <mixed-citation>Duan L, Yan Y, Liu J, Wang B, Li P, Hu Q, et al. Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C. Sci Rep. 2016;6:24867</mixed-citation>
      </ref>
      <ref id="ref37">
        <label>37</label>
        <mixed-citation>Adesina SK, Akala EO. Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol Pharm. 2015;12(12):4175-4187</mixed-citation>
      </ref>
      <ref id="ref38">
        <label>38</label>
        <mixed-citation>Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. Anal Chem. 2016;88(21):10661-10666</mixed-citation>
      </ref>
      <ref id="ref39">
        <label>39</label>
        <mixed-citation>Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother. 2006;60(9):607-620</mixed-citation>
      </ref>
      <ref id="ref40">
        <label>40</label>
        <mixed-citation>Bawa R. Nanopharmaceuticals: nanopharmaceuticals. Eur J Nanomed. 2010;3(1):34-40</mixed-citation>
      </ref>
      <ref id="ref41">
        <label>41</label>
        <mixed-citation>Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, et al. New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38(Suppl 1):335-347</mixed-citation>
      </ref>
      <ref id="ref42">
        <label>42</label>
        <mixed-citation>Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2(8):469-478</mixed-citation>
      </ref>
      <ref id="ref43">
        <label>43</label>
        <mixed-citation>Zazo H, Colino CI, Lanao JM. Current applications of nanoparticles in infectious diseases. J Control Release. 2016;224:86-102</mixed-citation>
      </ref>
      <ref id="ref44">
        <label>44</label>
        <mixed-citation>Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1-2):113-142</mixed-citation>
      </ref>
      <ref id="ref45">
        <label>45</label>
        <mixed-citation>Baram-Pinto D, Shukla S, Richman M, Gedanken A, Rahimipour S, Sarid R. Surface-modified protein nanospheres as potential antiviral agents. Chem Commun (Camb). 2012;48(66):8359-8361</mixed-citation>
      </ref>
      <ref id="ref46">
        <label>46</label>
        <mixed-citation>Bergeron MG, Desormeaux A. Liposomes encapsulating antiviral drugs. US Patent 5,773,027. 1998</mixed-citation>
      </ref>
      <ref id="ref47">
        <label>47</label>
        <mixed-citation>Dutta T, Agashe HB, Garg M, Balasubramanium P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J Drug Target. 2007;15(1):89-98</mixed-citation>
      </ref>
      <ref id="ref48">
        <label>48</label>
        <mixed-citation>Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl. 2010;49(19):3280-3294</mixed-citation>
      </ref>
      <ref id="ref49">
        <label>49</label>
        <mixed-citation>Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and drug delivery part 2: nanostructures for drug delivery. Trop J Pharm Res. 2009;8(3):275-287</mixed-citation>
      </ref>
      <ref id="ref50">
        <label>50</label>
        <mixed-citation>Stevanovic M, Uskokovic D. Poly (lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr Nanosci. 2009;5(1):1-14</mixed-citation>
      </ref>
      <ref id="ref51">
        <label>51</label>
        <mixed-citation>Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. Vaccine. 2014;32(3):327-337</mixed-citation>
      </ref>
      <ref id="ref52">
        <label>52</label>
        <mixed-citation>Aggarwal P, Hall JB, McClelland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428-437</mixed-citation>
      </ref>
      <ref id="ref53">
        <label>53</label>
        <mixed-citation>Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS One. 2011;6(4):e18270</mixed-citation>
      </ref>
      <ref id="ref54">
        <label>54</label>
        <mixed-citation>Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliv Rev. 2010;62(5):560-575</mixed-citation>
      </ref>
      <ref id="ref55">
        <label>55</label>
        <mixed-citation>Mignani S, Majoral JP. Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview. New J Chem. 2013;37(11):3337-3357</mixed-citation>
      </ref>
      <ref id="ref56">
        <label>56</label>
        <mixed-citation>Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20</mixed-citation>
      </ref>
      <ref id="ref57">
        <label>57</label>
        <mixed-citation>Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65(3):259-269</mixed-citation>
      </ref>
      <ref id="ref58">
        <label>58</label>
        <mixed-citation>Zeng P, Xu Y, Zeng C, Ren H, Peng M. Chitosan-modified poly (D, L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm. 2011;415(1-2):259-266</mixed-citation>
      </ref>
      <ref id="ref59">
        <label>59</label>
        <mixed-citation>Dehghan S, Kheiri MT, Tabatabaiean M, Darabi S, Tafaghodi M. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. Arch Pharm Res. 2013;36(8):981-992</mixed-citation>
      </ref>
      <ref id="ref60">
        <label>60</label>
        <mixed-citation>Mohajer M, Khameneh B, Tafaghodi M. Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin. Iran J Basic Med Sci. 2014;17(9):722-726</mixed-citation>
      </ref>
      <ref id="ref61">
        <label>61</label>
        <mixed-citation>Gregory AE, Williamson D, Titball R. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013;3:13</mixed-citation>
      </ref>
      <ref id="ref62">
        <label>62</label>
        <mixed-citation>Thorley AJ, Tetley TD. New perspectives in nanomedicine. Pharmacol Ther. 2013;140(2):176-185</mixed-citation>
      </ref>
      <ref id="ref63">
        <label>63</label>
        <mixed-citation>Kuntworbe N, Martini N, Shaw J, Al-Kassas R. Malaria intervention policies and pharmaceutical nanotechnology as a potential tool for malaria management. Drug Dev Res. 2012;73(4):167-184</mixed-citation>
      </ref>
      <ref id="ref64">
        <label>64</label>
        <mixed-citation>Amin R. Nanotechnology in controlling infectious disease. In: Hunter RJ, Preedy VR, editors. Nanomedicine in health and disease. Enfield, NH: Science Publishers; 2011. p. 167-183</mixed-citation>
      </ref>
      <ref id="ref65">
        <label>65</label>
        <mixed-citation>Garnett MC. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev. 2001;53(2):171-216</mixed-citation>
      </ref>
      <ref id="ref66">
        <label>66</label>
        <mixed-citation>Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364(2):272-280</mixed-citation>
      </ref>
      <ref id="ref67">
        <label>67</label>
        <mixed-citation>Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release. 2002;82(2-3):189-212</mixed-citation>
      </ref>
      <ref id="ref68">
        <label>68</label>
        <mixed-citation>Arifin DR, Palmer AF. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules. 2005;6(4):2172-2181</mixed-citation>
      </ref>
      <ref id="ref69">
        <label>69</label>
        <mixed-citation>Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761-769</mixed-citation>
      </ref>
      <ref id="ref70">
        <label>70</label>
        <mixed-citation>Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf B Biointerfaces. 2010;79(2):467-479</mixed-citation>
      </ref>
      <ref id="ref71">
        <label>71</label>
        <mixed-citation>Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8(24):1112-1120</mixed-citation>
      </ref>
      <ref id="ref72">
        <label>72</label>
        <mixed-citation>Caminade AM, Laurent R, Majoral JP. Characterization of dendrimers. Adv Drug Deliv Rev. 2005;57(15):2130-2146</mixed-citation>
      </ref>
      <ref id="ref73">
        <label>73</label>
        <mixed-citation>Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177</mixed-citation>
      </ref>
      <ref id="ref74">
        <label>74</label>
        <mixed-citation>Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62(4-5):478-490</mixed-citation>
      </ref>
      <ref id="ref75">
        <label>75</label>
        <mixed-citation>Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011;7(5):632-639</mixed-citation>
      </ref>
      <ref id="ref76">
        <label>76</label>
        <mixed-citation>Xie S, Tao Y, Pan Y, Qu W, Cheng G, Huang L, et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. J Control Release. 2014;187:101-117</mixed-citation>
      </ref>
      <ref id="ref77">
        <label>77</label>
        <mixed-citation>Thakkar KN, Mhatre SS, Parikh RY. Biological synthesis of metallic nanoparticles. Nanomedicine. 2010;6(2):257-262</mixed-citation>
      </ref>
      <ref id="ref78">
        <label>78</label>
        <mixed-citation>Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, Jiang X. The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli. Biomaterials. 2012;33(7):2327-2333</mixed-citation>
      </ref>
      <ref id="ref79">
        <label>79</label>
        <mixed-citation>Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1(3):325-327</mixed-citation>
      </ref>
      <ref id="ref80">
        <label>80</label>
        <mixed-citation>Skirtach AG, Muñoz Javier A, Kreft O, Köhler K, Piera Alberola A, Möhwald H, et al. Laser-induced release of encapsulated materials inside living cells. Angew Chem Int Ed Engl. 2006;45(28):4612-4617</mixed-citation>
      </ref>
      <ref id="ref81">
        <label>81</label>
        <mixed-citation>Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60(11):1307-1315</mixed-citation>
      </ref>
      <ref id="ref82">
        <label>82</label>
        <mixed-citation>Schmid G. Large clusters and colloids. Metals in the embryonic state. Chem Rev. 1992;92(8):1709-1727</mixed-citation>
      </ref>
      <ref id="ref83">
        <label>83</label>
        <mixed-citation>Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R. Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid–liquid system. J Chem Soc Chem Commun. 1994;(7):801-802</mixed-citation>
      </ref>
      <ref id="ref84">
        <label>84</label>
        <mixed-citation>Templeton AC, Wuelfing WP, Murray RW. Monolayer-protected cluster molecules. Acc Chem Res. 2000;33(1):27-36</mixed-citation>
      </ref>
      <ref id="ref85">
        <label>85</label>
        <mixed-citation>Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc. 1951;11:55-75</mixed-citation>
      </ref>
      <ref id="ref86">
        <label>86</label>
        <mixed-citation>Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nature. 1973;241(105):20-22</mixed-citation>
      </ref>
      <ref id="ref87">
        <label>87</label>
        <mixed-citation>Grabar KC, Freeman RG, Hommer MB, Natan MJ. Preparation and characterization of Au colloid monolayers. Anal Chem. 1995;67(4):735-743</mixed-citation>
      </ref>
      <ref id="ref88">
        <label>88</label>
        <mixed-citation>Gong P, Li H, He X, Wang K, Hu J, Tan W, et al. Preparation and antibacterial activity of Fe3O4@Ag nanoparticles. Nanotechnology. 2007;18(28):285604</mixed-citation>
      </ref>
      <ref id="ref89">
        <label>89</label>
        <mixed-citation>Cho KH, Park JE, Osaka T, Park SG. The study of antimicrobial activity and preservative effects of nanosilver ingredient. Electrochim Acta. 2005;51(5):956-960</mixed-citation>
      </ref>
      <ref id="ref90">
        <label>90</label>
        <mixed-citation>Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27(1):76-83</mixed-citation>
      </ref>
      <ref id="ref91">
        <label>91</label>
        <mixed-citation>Huh AJ, Kwon YJ. 'Nanoantibiotics': a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release. 2011;156(2):128-145</mixed-citation>
      </ref>
      <ref id="ref92">
        <label>92</label>
        <mixed-citation>Lara HH, Garza-Treviño EN, Ixtepan-Turrent L, Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnology. 2011;9:30</mixed-citation>
      </ref>
      <ref id="ref93">
        <label>93</label>
        <mixed-citation>Gerrity D, Ryu H, Crittenden J, Abbaszadegan M. Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2008;43(12):1261-1270</mixed-citation>
      </ref>
      <ref id="ref94">
        <label>94</label>
        <mixed-citation>Antoine TE, Mishra YK, Trigilio J, Tiwari V, Adelung R, Shukla D. Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. Antiviral Res. 2012;96(3):363-375</mixed-citation>
      </ref>
      <ref id="ref95">
        <label>95</label>
        <mixed-citation>Ingle AP, Duran N, Rai M. Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: a review. Appl Microbiol Biotechnol. 2014;98(3):1001-1009</mixed-citation>
      </ref>
      <ref id="ref96">
        <label>96</label>
        <mixed-citation>Yadavalli T, Shukla D. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomedicine (Lond). 2017;13(1):219-230</mixed-citation>
      </ref>
      <ref id="ref97">
        <label>97</label>
        <mixed-citation>Yang ZH, Zhuo Y, Yuan R, Chai YQ. An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO2 nanocomposites as signal enhancer. Biosens Bioelectron. 2015;69:321-327</mixed-citation>
      </ref>
      <ref id="ref98">
        <label>98</label>
        <mixed-citation>Chaudhuri RG, Paria S. Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. Chem Rev. 2012;112(4):2373-2433</mixed-citation>
      </ref>
      <ref id="ref99">
        <label>99</label>
        <mixed-citation>Tojo C, Buceta D, López-Quintela MA. Core-shell nanocatalysts obtained in reverse micelles: structural and kinetic aspects. J Nanomater. 2015;2015:1-10</mixed-citation>
      </ref>
      <ref id="ref100">
        <label>100</label>
        <mixed-citation>Chatterjee K, Sarkar S, Rao KJ, Paria S. Core/shell nanoparticles in biomedical applications. Adv Colloid Interface Sci. 2014;209:8-39</mixed-citation>
      </ref>
      <ref id="ref101">
        <label>101</label>
        <mixed-citation>Cheong S, Ferguson P, Hermans IF, Jameson GN, Tilley RD. Synthesis and stability of highly crystalline and stable iron/iron oxide core/shell nanoparticles for biomedical applications. ChemPlusChem. 2012;77(2):135-140</mixed-citation>
      </ref>
      <ref id="ref102">
        <label>102</label>
        <mixed-citation>Varanda LC, Imaizumi M, Santos FJ, Jafelicci M. Iron oxide versus Fe55Pt45/Fe3O4: improved magnetic properties of core/shell nanoparticles for biomedical applications. IEEE Trans Magn. 2008;44(11):4448-4451</mixed-citation>
      </ref>
      <ref id="ref103">
        <label>103</label>
        <mixed-citation>Arias JL, López-Viota M, Ruiz MA, López-Viota J, Delgado AV. Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. Int J Pharm. 2007;339(1-2):237-245</mixed-citation>
      </ref>
      <ref id="ref104">
        <label>104</label>
        <mixed-citation>Herzog C, Hartmann K, Künzi V, Kursteiner O, Mischler R, Lazar H, et al. Eleven years of Inflexal® V – a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27(33):4381-4387</mixed-citation>
      </ref>
      <ref id="ref105">
        <label>105</label>
        <mixed-citation>Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine. 2002;20(Suppl 5):B17-B23</mixed-citation>
      </ref>
      <ref id="ref106">
        <label>106</label>
        <mixed-citation>Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-796</mixed-citation>
      </ref>
      <ref id="ref107">
        <label>107</label>
        <mixed-citation>Bovier PA. Epaxal®: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines. 2008;7(8):1141-1150</mixed-citation>
      </ref>
      <ref id="ref108">
        <label>108</label>
        <mixed-citation>Alconcel SNS, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polym Chem. 2011;2(7):1442-1448</mixed-citation>
      </ref>
      <ref id="ref109">
        <label>109</label>
        <mixed-citation>Waknine Y. International approvals: Avalox IV, Pegasys, Influvac. Medscape. 2005</mixed-citation>
      </ref>
      <ref id="ref110">
        <label>110</label>
        <mixed-citation>Sirnaomics. Advancing RNAi therapeutics. 2016. Accessed November 24, 2016</mixed-citation>
      </ref>
      <ref id="ref111">
        <label>111</label>
        <mixed-citation>Starpharma. VivaGel active against Zika virus. 2016. Accessed October 10, 2016</mixed-citation>
      </ref>
      <ref id="ref112">
        <label>112</label>
        <mixed-citation>Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, MaWhinney S, et al. Safety, tolerability and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. J Acquir Immune Defic Syndr. 2013;64(4):351-359</mixed-citation>
      </ref>
      <ref id="ref113">
        <label>113</label>
        <mixed-citation>Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine is non-inferior to darunavir/r in phase 3 treatment-naive trial at week 48. In: Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections (CROI 2017). Seattle, WA; February 13-16, 2017. Abstract 45LB</mixed-citation>
      </ref>
      <ref id="ref114">
        <label>114</label>
        <mixed-citation>Seto WK, Yuen MF. New pharmacological approaches to a functional cure of hepatitis B. Clin Liver Dis. 2016;8(4):83-88</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
